

The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM D

OMB APPROVAL

OMB Number: 3235-0076

Estimated average burden

hours per response: 4.00

Notice of Exempt Offering of Securities

1. Issuer's Identity

CIK (Filer ID Number)

0001788028

Name of Issuer

Jasper Therapeutics, Inc.

Jurisdiction of Incorporation/Organization

DELAWARE

Year of Incorporation/Organization



Over Five Years Ago



Within Last Five Years (Specify Year)



Yet to Be Formed

Previous
Names



None

Amplitude Healthcare Acquisition Corp

Amplitude Healthcare Acquisition Corporation

Entity Type



Corporation



Limited Partnership



Limited Liability Company



General Partnership



Business Trust



Other (Specify)

2. Principal Place of Business and Contact Information

Name of Issuer

Jasper Therapeutics, Inc.

Street Address 1

2200 BRIDGE PKWY

Street Address 2

SUITE #102

City

REDWOOD CITY

State/Province/Country

CALIFORNIA

ZIP/PostalCode

94065

Phone Number of Issuer

650-549-1400

3. Related Persons

Last Name

Cross

First Name

Herb

Middle Name

Street Address 1

2200 Bridge Pkwy

Street Address 2

Suite #102

City

Redwood City

State/Province/Country

CALIFORNIA

ZIP/PostalCode

94065

Relationship: ☒ Executive Officer ☐ Director ☐ Promoter

Clarification of Response (if Necessary):

Last Name

Mahal

First Name

Jeet

Middle Name

Street Address 1

2200 Bridge Pkwy

Street Address 2

Suite #102

City

Redwood City

State/Province/Country

CALIFORNIA

ZIP/PostalCode

94065

Relationship: ☒ Executive Officer ☒ Director ☐ Promoter

Clarification of Response (if Necessary):

Last Name

Crutcher

First Name

Patrick

Middle Name

Street Address 1

2200 Bridge Pkwy

Street Address 2

Suite #102

City

Redwood City

State/Province/Country

CALIFORNIA

ZIP/PostalCode

94065

Relationship: ☐ Executive Officer ☒ Director ☐ Promoter

Clarification of Response (if Necessary):

Last Name	First Name	Middle Name
Wiggans	Thomas	
Street Address 1	Street Address 2	
2200 Bridge Pkwy	Suite #102	
City	State/Province/Country	ZIP/PostalCode
Redwood City	CALIFORNIA	94065
Relationship: ☐ Executive Officer ☒ Director ☐ Promoter		
Clarification of Response (if Necessary):		

Last Name	First Name	Middle Name
Shizuru	Judith	
Street Address 1	Street Address 2	
2200 Bridge Pkwy	Suite #102	
City	State/Province/Country	ZIP/PostalCode
Redwood City	CALIFORNIA	94065
Relationship: ☐ Executive Officer ☒ Director ☐ Promoter		
Clarification of Response (if Necessary):		

Last Name	First Name	Middle Name
Lucas	Svetlana	
Street Address 1	Street Address 2	
2200 Bridge Pkwy	Suite #102	
City	State/Province/Country	ZIP/PostalCode
Redwood City	CALIFORNIA	94065
Relationship: ☐ Executive Officer ☒ Director ☐ Promoter		
Clarification of Response (if Necessary):		

Last Name	First Name	Middle Name
von Emster	Kurt	
Street Address 1	Street Address 2	
2200 Bridge Pkwy	Suite #102	
City	State/Province/Country	ZIP/PostalCode
Redwood City	CALIFORNIA	94065
Relationship: ☐ Executive Officer ☒ Director ☐ Promoter		
Clarification of Response (if Necessary):		

Last Name	First Name	Middle Name
Song	Wenru	
Street Address 1	Street Address 2	
2200 Bridge Pkwy	Suite #102	
City	State/Province/Country	ZIP/PostalCode
Redwood City	CALIFORNIA	94065
Relationship: ☒ Executive Officer ☐ Director ☐ Promoter		
Clarification of Response (if Necessary):		

Last Name	First Name	Middle Name
Keenan	Gregory	F.
Street Address 1	Street Address 2	
2200 Bridge Pkwy	Suite #102	
City	State/Province/Country	ZIP/PostalCode
Redwood City	CALIFORNIA	94065
Relationship: ☒ Executive Officer ☐ Director ☐ Promoter		
Clarification of Response (if Necessary):		

Last Name	First Name	Middle Name
Ros	Matthew	E.
Street Address 1	Street Address 2	

2200 Bridge Pkwy

Suite #102

City

State/Province/Country

ZIP/PostalCode

Redwood City

CALIFORNIA

94065

Relationship: ☐ Executive Officer ☒ Director ☐ Promoter

Clarification of Response (if Necessary):

4. Industry Group

- | | | |
|---|---|--|
| ☐ Agriculture | Health Care | ☐ Retailing |
| ☐ Banking & Financial Services | ☒ Biotechnology | ☐ Restaurants |
| ☐ Commercial Banking | ☐ Health Insurance | ☐ Technology |
| ☐ Insurance | ☐ Hospitals & Physicians | ☐ Computers |
| ☐ Investing | ☐ Pharmaceuticals | ☐ Telecommunications |
| ☐ Investment Banking | ☐ Other Health Care | ☐ Other Technology |
| ☐ Pooled Investment Fund | ☐ Manufacturing | ☐ Travel |
| Is the issuer registered as an investment company under the Investment Company Act of 1940? | ☐ Real Estate | ☐ Airlines & Airports |
| ☐ Yes ☐ No | ☐ Commercial | ☐ Lodging & Conventions |
| ☐ Other Banking & Financial Services | ☐ Construction | ☐ Tourism & Travel Services |
| ☐ Business Services | ☐ REITS & Finance | ☐ Other Travel |
| ☐ Energy | ☐ Residential | ☐ Other |
| ☐ Coal Mining | ☐ Other Real Estate | |
| ☐ Electric Utilities | | |
| ☐ Energy Conservation | | |
| ☐ Environmental Services | | |
| ☐ Oil & Gas | | |
| ☐ Other Energy | | |

5. Issuer Size

- | | | |
|---|----|---|
| Revenue Range | OR | Aggregate Net Asset Value Range |
| ☐ No Revenues | | ☐ No Aggregate Net Asset Value |
| ☐ \$1 - \$1,000,000 | | ☐ \$1 - \$5,000,000 |
| ☐ \$1,000,001 - \$5,000,000 | | ☐ \$5,000,001 - \$25,000,000 |
| ☐ \$5,000,001 - \$25,000,000 | | ☐ \$25,000,001 - \$50,000,000 |
| ☐ \$25,000,001 - \$100,000,000 | | ☐ \$50,000,001 - \$100,000,000 |
| ☐ Over \$100,000,000 | | ☐ Over \$100,000,000 |
| ☒ Decline to Disclose | | ☐ Decline to Disclose |
| ☐ Not Applicable | | ☐ Not Applicable |

6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

- | | | |
|--|--|---|
| ☐ Rule 504(b)(1) (not (i), (ii) or (iii)) | ☐ Investment Company Act Section 3(c) | |
| ☐ Rule 504 (b)(1)(i) | ☐ Section 3(c)(1) | ☐ Section 3(c)(9) |
| ☐ Rule 504 (b)(1)(ii) | ☐ Section 3(c)(2) | ☐ Section 3(c)(10) |
| ☐ Rule 504 (b)(1)(iii) | ☐ Section 3(c)(3) | ☐ Section 3(c)(11) |
| ☒ Rule 506(b) | ☐ Section 3(c)(4) | ☐ Section 3(c)(12) |
| ☐ Rule 506(c) | ☐ Section 3(c)(5) | ☐ Section 3(c)(13) |
| ☐ Securities Act Section 4(a)(5) | ☐ Section 3(c)(6) | ☐ Section 3(c)(14) |
| | ☐ Section 3(c)(7) | |

7. Type of Filing

- ☒ New Notice Date of First Sale [2026-07-21](#) ☐ First Sale Yet to Occur
- ☐ Amendment

8. Duration of Offering

Does the Issuer intend this offering to last more than one year? ☐ Yes ☒ No

9. Type(s) of Securities Offered (select all that apply)

- ☒ Equity
- ☐ Debt
- ☐ Option, Warrant or Other Right to Acquire Another Security
- ☐ Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security
- ☐ Pooled Investment Fund Interests
- ☐ Tenant-in-Common Securities
- ☐ Mineral Property Securities
- ☐ Other (describe)

10. Business Combination Transaction

Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer? ☐ Yes ☒ No

Clarification of Response (if Necessary):

11. Minimum Investment

Minimum investment accepted from any outside investor \$0 USD

12. Sales Compensation

Recipient

(Associated) Broker or Dealer ☒ None

Street Address 1

City

State(s) of Solicitation (select all that apply)
Check "All States" or check individual States ☐ All States

Recipient CRD Number ☒ None

(Associated) Broker or Dealer CRD Number ☒ None

Street Address 2

State/Province/Country

ZIP/Postal Code

☐ Foreign/non-US

13. Offering and Sales Amounts

Total Offering Amount

\$131,999,611 USD

or ☐ Indefinite

Total Amount Sold

\$131,999,611 USD

Total Remaining to be Sold

\$0 USD

or ☐ Indefinite

Clarification of Response (if Necessary):

14. Investors

☐ Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.

Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:

40

15. Sales Commissions & Finder's Fees Expenses

Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

Sales Commissions \$0 USD ☐ Estimate

Finders' Fees \$0 USD ☐ Estimate

Clarification of Response (if Necessary):

16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

\$0 USD

☐ Estimate

Clarification of Response (if Necessary):

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
Jasper Therapeutics, Inc.	/s/ Herb Cross	Herb Cross	Chief Financial Officer	2026-08-04

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

* This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.